Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy

Table 5 Clinical data pre- and post-anti-tumour necrosis factor therapy

	Non-responder (n = 12)	Responder (n = 12)	P value
	(n or mean ± SEM)	(n or mean ± SEM)
Pre-anti-TNF therapy
Immunosuppressant
Thiopurine	7	6	NS
Tacrolimus	2	0	NS
Prednisone	9	7	NS
Prednisone/thiopurine	6	2	NS
Methotrexate	1	0
5-ASA	6	5	NS
ESR	42.5 ± 12.9 (n = 7)	33.1 ± 10.4 (n = 7)	NS
CRP	36.3 ± 10.1 (n = 11)	27.4 ± 7.4 (n = 12)	NS
Partial Mayo1	7.3 ± 0.5 (n = 7)	7.5 ± 0.2 (n = 11)	NS
Post-anti-TNF therapy
Immunosuppressant
Thiopurine	12	8	NS
Tacrolimus	4	0	0.045
Prednisone	6	0	0.007
Prednisone/thiopurine	0	0
Methotrexate	0	0
5-ASA	6	4	NS
ESR	22.9 ± 7.9 (n = 4)	13.5 ± 4.7 (n = 9)	NS
CRP	51.2 ± 14.6 (n = 12)	4.6 ± 1.2 (n = 12)	0.0043
Partial Mayo1	7.6 ± 0.4 (n = 12)	0.3 ± 0.2 (n = 12)	< 0.0001

¹Partial Mayo scores presented as not all patients had endoscopic examination at time of blood draw. CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.